An IGRA measures your immune response to tuberculosis proteins, not whether tuberculosis bacteria are currently causing illness. The category matters, but exposure history, symptoms and immune status determine the next step.
- Positive IGRA means immune cells recognized tuberculosis-specific proteins; it does not prove active tuberculosis or tell when exposure occurred.
- QuantiFERON positive threshold is typically TB1-Nil or TB2-Nil at least 0.35 IU/mL and at least 25% of the Nil value.
- T-SPOT.TB positive threshold is commonly 8 or more antigen spots above the Nil control; 5–7 spots may be reported as borderline in some laboratories.
- Negative IGRA makes TB infection less likely only when the Mitogen control responds adequately and exposure was not within the last 8 weeks.
- Indeterminate IGRA result means the controls failed, often from low immune responsiveness or high background signal, rather than a positive or negative TB answer.
- BCG vaccination does not usually cause a positive IGRA because IGRA antigens ESAT-6 and CFP-10 are absent from BCG vaccine strains.
- Active TB exclusion requires symptom review, chest imaging and microbiology testing; neither IGRA nor a TB skin test can distinguish active from latent infection.
- Urgent symptoms include coughing blood, worsening breathlessness, persistent fever, drenching night sweats or unexplained weight loss; seek same-day medical assessment.
What each IGRA category means in plain language
IGRA test results are reported as positive, negative or indeterminate. A positive result supports TB infection, a negative result lowers its likelihood, and an indeterminate result means the laboratory controls did not permit interpretation; none of the three categories alone diagnoses active tuberculosis.
The test is performed on a laboratory sample containing living white cells, which are exposed to selected Mycobacterium tuberculosis proteins. If sensitized T cells release interferon-gamma, the assay is positive. Kantesti is an AI blood test analyzer that can place an uploaded IGRA report alongside its stated controls, units and other laboratory findings, but it cannot establish TB activity from a result category alone.
A result is not a risk score. A QuantiFERON value of 0.36 IU/mL may be technically positive, yet it sits just above the usual 0.35 IU/mL threshold and deserves more attention to exposure probability than a result of 8.0 IU/mL. As Dr. Thomas Klein, I have seen unnecessary alarm when a patient reads “positive” as synonymous with contagious disease.
The 2017 ATS/CDC/IDSA diagnostic guideline states that IGRA and tuberculin skin testing identify TB infection but do not distinguish latent infection from active disease (Lewinsohn et al., 2017). That distinction is made clinically, usually with a symptom screen, chest radiograph and respiratory samples where indicated. Our guide to a positive antibody result explains why immune recognition tests need this same context.
How QuantiFERON and T-SPOT measure TB immunity
IGRAs detect interferon-gamma released by T lymphocytes after stimulation with TB-specific antigens. QuantiFERON measures interferon-gamma concentration in IU/mL, whereas T-SPOT.TB counts responding cellular spots; their result formats are not interchangeable.
QuantiFERON-TB Gold Plus uses two antigen tubes, TB1 and TB2, plus a Nil background tube and Mitogen positive-control tube. A usual positive criterion is TB1-Nil or TB2-Nil of at least 0.35 IU/mL and at least 25% of Nil. The Mitogen control should generally produce at least 0.50 IU/mL above Nil for a confidently negative assay.
T-SPOT.TB standardizes the number of peripheral blood mononuclear cells placed in each well, then counts interferon-gamma-producing cells as spots. In commonly used interpretation criteria, 8 or more spots above Nil is positive, 5–7 spots is borderline, and 4 or fewer is negative, provided controls are valid. Laboratories may use region-specific report language, so read the laboratory’s own reference notes.
A very high Nil control can obscure the true signal, while a poor Mitogen response suggests cells did not respond even to a broad stimulant. That is why a binary-looking report contains quality-control data worth checking. For a wider explanation of specimen and assay terminology, see our serum versus plasma guide.
What a positive IGRA test usually means
A positive IGRA test meaning is that your immune system has previously recognized proteins associated with Mycobacterium tuberculosis. It supports TB infection, but it does not identify the date, location, severity or current activity of infection.
Positive results are most clinically persuasive after close household exposure, birth or prolonged residence in a high-incidence setting, or before immunosuppressive therapy. In a person with almost no exposure likelihood, a low-level result near 0.35 IU/mL has a lower positive predictive value than the same result in a household contact. Pre-test probability changes the meaning of every screening test.
Neither interferon-gamma concentration nor spot number measures bacterial burden. A 4.5 IU/mL result does not mean “more infectious” than 0.5 IU/mL, and a patient with active pulmonary TB can have a modest positive value. In my clinical experience, numeric over-reading is one of the commonest sources of distress after an IGRA report.
A positive test should trigger a medical history, examination and chest imaging before latent-TB treatment is discussed. Symptoms such as cough lasting 2–3 weeks, fever, night sweats or involuntary weight loss change the pathway immediately. If a complete blood count is also available, our lymphocyte range explainer can help frame immune-cell context, without substituting for TB assessment.
Why a positive result cannot separate latent from active TB
A positive IGRA cannot distinguish latent TB infection from active TB disease because both states can leave circulating T cells able to recognize TB antigens. This limitation applies even when the interferon-gamma value is very high.
Latent TB infection means immune evidence of infection without symptoms, radiographic evidence or microbiologic evidence of active disease. Active TB disease means bacteria are causing illness and may be transmissible, especially when the lungs or airways are involved. An IGRA detects the host response shared by both states, not bacteria in a particular organ.
Chest radiography is normally the first exclusion step after a positive IGRA in an asymptomatic person. An abnormal image, respiratory symptoms or HIV-related immune compromise usually prompts sputum nucleic-acid amplification testing, smear microscopy and culture; culture can take several weeks but provides drug-susceptibility information. A normal chest radiograph reduces concern for pulmonary disease but does not fully exclude every form of TB.
WHO guidance on TB diagnosis similarly cautions against using IGRA or TST to diagnose active disease in adults (World Health Organization, 2021). A persistent cough plus a positive IGRA is a same-day clinical issue, not an app interpretation exercise. Review our shortness-of-breath blood test guide for other urgent laboratory-context signals that can coexist with respiratory symptoms.
When a negative IGRA is reassuring—and when it is not
A negative IGRA means TB antigens did not produce a qualifying interferon-gamma response while the test controls performed properly. It makes TB infection less likely, but it does not reliably exclude very recent exposure, active TB or immune suppression.
The immune system may need 2 to 8 weeks after exposure to develop a measurable response. CDC advises repeating a negative IGRA 8 to 10 weeks after the last exposure in a close contact, because a test performed during the early window can be falsely negative (Mazurek et al., 2010). A negative test from day 3 is not a final clearance result.
Advanced HIV, chemotherapy, organ transplantation, high-dose corticosteroids and severe acute illness can reduce T-cell responsiveness. Prednisolone at doses of 15 mg daily or more for 1 month is often treated as clinically meaningful immunosuppression when TB risk is being assessed, although the exact effect on any individual assay is variable. Negative testing under these conditions needs specialist judgment.
Kantesti AI highlights whether an uploaded report states a valid Mitogen control rather than treating “negative” as universally reassuring. This is one reason our immune-system test overview is useful when immunity or medication history complicates an otherwise simple result.
What causes an indeterminate IGRA result
An indeterminate IGRA result is a failed test-quality outcome, not evidence for or against TB infection. In QuantiFERON testing, it commonly arises from a Mitogen-Nil value below 0.50 IU/mL or a Nil value above 8.0 IU/mL.
A weak Mitogen response means the sample’s lymphocytes did not show an expected broad immune response. This can occur with lymphopenia, severe illness, immunosuppressive medicines, delayed sample incubation or simple pre-analytic handling problems. It does not mean the person has TB, and it should not be recorded as a positive screen.
A high Nil response means background interferon-gamma was already elevated before TB antigens were added. Autoimmune activity, another infection, laboratory handling and occasional unexplained biological variation can contribute. In a T-SPOT.TB assay, excessively high Nil spot counts or inadequate positive-control spots may instead be reported as invalid.
Repeat testing is sensible once a temporary illness has resolved, ideally with careful collection and prompt laboratory transport. Kantesti is an AI lab test interpretation service that can identify a stated Nil or Mitogen control failure on the report, while the ordering clinician decides whether repeat IGRA, TST or active-TB investigation is appropriate. Our article on retesting after a lab error covers why specimen quality can alter results.
Why BCG vaccination rarely affects IGRA results
BCG vaccination does not usually cause a positive IGRA because standard IGRAs use ESAT-6 and CFP-10 antigens that are absent from BCG vaccine strains. This is the practical advantage of IGRA over a TB skin test in BCG-vaccinated people.
The tuberculin skin test uses purified protein derivative, a broad mixture that overlaps with BCG and many environmental mycobacteria. IGRA antigen selection was designed to narrow that cross-reactivity. Kantesti is an AI blood test interpretation platform that explains this BCG distinction when readers upload a result, though the report still needs exposure and symptom context.
There are exceptions worth knowing. ESAT-6 and CFP-10 are found in a small group of non-tuberculous mycobacteria, particularly M. kansasii, M. marinum and M. szulgai, so infection with these organisms can occasionally produce a positive IGRA. This is uncommon but matters in people with aquarium exposure, certain occupational exposures or compatible lung disease.
BCG may still matter when interpreting an old skin-test record, especially if vaccination occurred after infancy or was repeated. A positive IGRA in someone vaccinated at birth should not be dismissed as “just BCG.” For a broader look at interpreting immune test positives, see our ANA test results guide.
IGRA test vs TB skin test: choosing the right test
In the IGRA test vs TB skin test comparison, IGRA is often preferred for BCG-vaccinated adults and people unlikely to return for skin-test reading. The skin test remains useful where IGRA is unavailable, cost-prohibitive or locally recommended.
An IGRA requires one sample collection and laboratory processing, while a tuberculin skin test must be measured 48 to 72 hours after placement. Missing that reading window makes the skin test unusable. The skin test can also boost subsequent tests in serial screening, a phenomenon less relevant to IGRA.
Neither option is a general population screening test in low-risk adults. US and UK guidance generally favors targeted testing of people with exposure, migration-related risk, occupational risk or planned immunosuppression because false positives become more likely as baseline risk falls. Testing without a reason can create a cascade of avoidable imaging and anxiety.
For children younger than 5 years, practices differ by country and service; some clinicians prefer a skin test because paediatric IGRA data are less consistent and sample handling can be harder. The children’s lab interpretation guide explains why adult thresholds and reports cannot simply be transplanted into paediatric care.
Timing, borderline values and changing IGRA results
IGRA values close to the assay cutoff can change category on repeat testing because of normal biological and laboratory variation. A new result just above 0.35 IU/mL should be interpreted with exposure timing and absolute risk, not treated as a precise measure of infection severity.
For a close contact, test once promptly to establish a baseline and repeat 8–10 weeks after the last exposure if the first test is negative. A positive test during this interval warrants active-disease assessment immediately; one does not wait for the later test. This approach catches delayed immune conversion without delaying safety evaluation.
Some laboratories describe a borderline zone for QuantiFERON research or local occupational policies, often around 0.20–0.70 IU/mL, but this is not a universal manufacturer diagnostic category. T-SPOT.TB has a formal borderline category in many settings at 5–7 spots. Clinicians disagree on automatic retesting thresholds because patient risk often matters more than a narrow numerical band.
Serial testing in healthcare workers has produced apparent conversions and reversions near the cutoff even without known exposure. Recording the assay brand, Nil, TB1, TB2 and Mitogen values is far more useful than saving only “positive” or “negative.” Our lab-results timeline guide shows what to preserve before a repeat test.
Who needs faster follow-up after an IGRA result
People with a positive IGRA need faster follow-up when they have TB symptoms, close exposure, HIV, immune-suppressing treatment or a planned TNF-inhibitor or transplant regimen. A positive result in an otherwise well, low-risk person is usually urgent in days rather than minutes, but should not be ignored.
Highest-priority groups include household contacts of contagious pulmonary TB, people with HIV, recipients of solid-organ or stem-cell transplants, and those starting anti-TNF treatment. Risk of progression is greatest soon after infection and when cellular immunity is impaired. A chest radiograph is generally obtained before preventive therapy to avoid missing active disease.
Pregnancy does not itself make an IGRA positive or negative, but symptoms, HIV status and exposure history still matter. In a pregnant person with exposure and symptoms, investigation for active TB should proceed without waiting for delivery. Preventive-treatment timing depends on the risk profile and local obstetric-TB expertise.
Dr. Thomas Klein’s practical advice is to bring the full report and a dated exposure timeline to the appointment, not a cropped portal screenshot. The health history tracker can help retain dates, medicines and previous imaging that meaningfully affect this decision.
Symptoms that require active tuberculosis assessment
A positive or negative IGRA does not overrule symptoms suggestive of active TB. Cough lasting 2–3 weeks, haemoptysis, persistent fever, drenching night sweats, chest pain, unexplained weight loss or worsening shortness of breath require prompt in-person evaluation.
Active pulmonary TB is assessed with a focused history, examination, chest radiograph and respiratory microbiology. Sputum nucleic-acid amplification can provide a rapid TB signal, while culture confirms disease and identifies susceptibility patterns. If sputum cannot be produced, clinicians may use induced sputum or bronchoscopy depending on severity and imaging findings.
A normal IGRA can occur in active TB, particularly in severe disease or impaired immunity. Conversely, a positive result can remain after successful treatment and should not be used to monitor whether treatment worked. Symptom change, imaging and microbiology are the appropriate markers of response.
Do not self-start antibiotics left over from another illness; partial treatment can complicate microbiological diagnosis. A raised inflammatory marker is non-specific, as discussed in our high ESR causes guide, and cannot confirm or exclude TB.
IGRA interpretation in children, pregnancy and immune suppression
IGRA interpretation is less reliable when T-cell function is impaired or sample handling is difficult. Young children, people with advanced HIV, patients receiving chemotherapy or high-dose steroids, and those who are acutely unwell have higher rates of false-negative or indeterminate results.
In children under 5 years, clinicians may use a skin test, IGRA or both according to local public-health guidance and exposure severity. A well child with a negative early test after a household exposure may still need repeat testing at 8–10 weeks. Infant and child contact management should be directed by paediatric or TB services, not delayed for an app result.
Anti-TNF medicines, JAK inhibitors, methotrexate, calcineurin inhibitors and systemic corticosteroids can affect TB risk and test responsiveness. Screening is best done before immune suppression begins whenever practical. If treatment cannot wait, specialists may use exposure history, imaging and dual-test strategies rather than relying on one negative result.
Kantesti is an AI-powered blood test analysis tool that can organize medication lists and related results around an IGRA report, but it does not determine whether preventive therapy is safe. For medication-linked trend review, our blood-test trend article explains the records clinicians actually need.
How to read the numbers and controls on your report
The most useful IGRA report includes assay name, collection date, antigen values, Nil value, Mitogen result and final laboratory interpretation. The final word alone hides whether a result was near a threshold or whether controls were weak.
For QuantiFERON, look for Nil, TB1-Nil, TB2-Nil and Mitogen-Nil. A TB1-Nil of 0.34 IU/mL is generally negative by the standard 0.35 IU/mL cutoff, but its practical meaning differs sharply between an asymptomatic low-risk worker and a recent household contact. The laboratory may also flag values outside the reportable range.
For T-SPOT.TB, locate the Nil spots, Panel A spots, Panel B spots and positive-control result. A result of 6 spots may be called borderline rather than negative, so follow-up often depends on exposure and local protocol. Never compare spot counts directly with QuantiFERON IU/mL values; they measure different analytical endpoints.
Kantesti AI interprets IGRA report components by keeping the assay methodology, controls and stated laboratory category together rather than converting a qualitative result into a diagnosis. Readers can review our AI report accuracy checklist and the technology guide to understand those safety boundaries.
Practical next steps after positive, negative or indeterminate results
After a positive IGRA, arrange clinical review and active-TB exclusion; after a valid negative test, repeat only if exposure was recent or risk remains high; after an indeterminate result, investigate control failure and usually repeat. The correct next step is determined by risk, symptoms and timing—not by the category alone.
Bring these five details to your appointment: the entire result report, date of last possible exposure, BCG history, current medicines and any symptoms. If active disease is excluded and latent infection is diagnosed, treatment options commonly include 3 months of weekly isoniazid plus rifapentine, 4 months of rifampicin, or other local protocols; regimen choice depends on drug interactions and country guidance.
Rifampicin and rifapentine can substantially reduce the effectiveness of hormonal contraception and interact with anticoagulants, antiretrovirals and transplant medicines. Baseline liver tests may be considered, especially with liver disease, alcohol use, pregnancy-related risk or interacting medicines; a single mildly abnormal ALT does not automatically rule out treatment. Our liver test abbreviation guide explains the usual panel components.
As of September 15, 2026, no consumer interpretation tool replaces a TB clinician’s decision to investigate infectious disease. Kantesti’s physician oversight and clinical standards are described by our Medical Advisory Board and medical validation process; use an uploaded report to prepare better questions, not to defer care.
Frequently Asked Questions
Can a positive IGRA test mean I have active tuberculosis?
A positive IGRA confirms that immune cells recognized TB-associated antigens, but it cannot tell whether infection is latent or active. Active TB assessment requires symptoms, chest imaging and, when appropriate, respiratory nucleic-acid testing and culture. A QuantiFERON value above 0.35 IU/mL is a positive immune-response threshold, not a measure of infectiousness. Anyone with cough lasting 2–3 weeks, fever, night sweats, weight loss or coughing blood should seek prompt clinical assessment.
Does BCG vaccination cause a positive IGRA result?
BCG vaccination does not usually cause a positive IGRA because standard assays use ESAT-6 and CFP-10 antigens that BCG vaccine strains do not contain. This differs from the TB skin test, which can be positive after BCG because it uses broader purified protein derivative. Rare cross-reactivity can occur with M. kansasii, M. marinum or M. szulgai infection. A positive IGRA in a person vaccinated with BCG at birth still needs standard medical follow-up.
What does an indeterminate QuantiFERON result mean?
An indeterminate QuantiFERON result means the assay controls failed, so the test cannot classify TB infection as positive or negative. It commonly occurs when Mitogen-Nil is below 0.50 IU/mL or Nil is above 8.0 IU/mL. Immune suppression, acute illness, lymphopenia and delayed laboratory processing are frequent explanations. Clinicians often repeat the test after recovery or choose a skin test or specialist assessment based on exposure risk.
How soon after TB exposure should I have an IGRA test?
An IGRA can be performed soon after a recognized TB exposure, but a negative result may not be reliable until the immune response develops. CDC commonly recommends repeating a negative test 8–10 weeks after the last exposure in close contacts. A positive result, symptoms or abnormal chest imaging should prompt assessment immediately rather than waiting for the repeat window. The date of the final exposure is more useful than the date the contact was first identified.
Can a negative IGRA rule out tuberculosis?
A valid negative IGRA lowers the likelihood of TB infection but does not rule out active tuberculosis or very recent infection. False-negative results are more likely during the first 2–8 weeks after exposure and in people with advanced HIV, severe illness or immune-suppressing medicines. A negative result must not delay assessment of persistent cough, fever, night sweats or weight loss. The Mitogen control should be adequate before a negative result is considered reliable.
Should I repeat a positive IGRA test after latent TB treatment?
A positive IGRA commonly remains positive after successful latent TB treatment, so repeating it does not prove cure and is generally not used to monitor treatment response. The 0.35 IU/mL QuantiFERON positivity threshold reflects immune recognition, which can persist after bacteria are cleared or contained. Follow-up instead focuses on medication adherence, adverse effects and new symptoms that could suggest active TB. Your clinician may document the original result to avoid unnecessary repeat screening in the future.
Get AI-Powered Blood Test Analysis Today
Join over 2 million users worldwide who trust Kantesti for instant, accurate lab test analysis. Upload your blood test results and receive comprehensive interpretation of 15,000+ biomarkers in seconds.
📚 Referenced Research Publications
Klein, T., Mitchell, S., & Weber, H. (2026). Diarrhea After Fasting, Black Specks in Stool & GI Guide 2026. Kantesti AI Medical Research.
Klein, T., Mitchell, S., & Weber, H. (2026). Women's Health Guide: Ovulation, Menopause & Hormonal Symptoms. Kantesti AI Medical Research.
📖 External Medical References
Mazurek GH et al. (2010). Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection—United States, 2010. MMWR Recommendations and Reports.
World Health Organization (2021). WHO consolidated guidelines on tuberculosis: module 3: diagnosis—rapid diagnostics for tuberculosis detection. World Health Organization.
⚕️ Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment decisions.
E-E-A-T Trust Signals
Experience
Physician-led clinical review of lab interpretation workflows.
Expertise
Laboratory medicine focus on how biomarkers behave in clinical context.
Authoritativeness
Written by Dr. Thomas Klein with review by Dr. Sarah Mitchell and Prof. Dr. Hans Weber.
Trustworthiness
Evidence-based interpretation with clear follow-up pathways to reduce alarm.